T Cell Proliferative Responses Against Human Papillomavirus Type 16 E7 Oncoprotein are Most Prominent in Cervical Intraepithelial Neoplasia Patients with a Persistent Viral Infection
T cell proliferative responses against human papillomavirus type 16 (HPV-16) E7 protein were studied in relation to HPV status over time in 51 women originally diagnosed with abnormal cervical cytology and participating in a follow-up study. HPV-16-positive patients were grouped as having either a persistent, a cleared or a fluctuating HPV-16 infection as determined by PCR in consecutive cervical smears up until the moment of testing. Positive proliferative responses against HPV-16 E7 were found in 15/26 patients with a persistent, cleared or fluctuating HPV-16 infection (57.7%). In contrast, 0/15 patients who had been typed HPV-negative during follow-up showed positive responses (P = 0.0005). Further analysis showed positive responses to be more frequent in patients with persistent HPV-16 infections and stable or progressing cervical lesions (8/9 patients reactive, 88.9%) as compared to patients with cleared or fluctuating HPV-16 infections and stable or regressing cervical lesions (7/17, 41.1%, P = 0.04). The relatively strong T cell proliferative responses against HPV-16 E7 observed in patients with a persistent HPV-16 infection and progressive cervical lesions indicate that the effectivity of such responses cannot be predicted and apparently depends on additional factors.
AltmannA.,
Jochmus-KudielkaJ.,
FrankR.,
GausepohlH.,
MoebiusU.,
GissmannL.,
MeuerS. C.1992; Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7. European Journal of Cancer 28:326–333
AppleR. J.,
ErlichH. A.,
KlitzW.,
ManosM. M.,
BeckerT. M.,
WheelerC. M.1994; HLA-DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nature Genetics 6:157–162
BalV.,
MclndoeA.,
DentonG.,
HudsonD.,
LombardiG.,
LambJ.,
LechlerR.1990; Antigen presentation by keratinocytes induces tolerance in human T cells. European Journal of Immunology 20:1893–1897
ChenL.,
Kinney ThomasE.,
HuS.-L.,
HellstromI.,
HellsromK. E.1991; Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proceedings of the National Academy of Sciences, USA 88:110–114
ComerfordS. A.,
McCanceD. J.,
DouganG.,
TiteJ. P.1991; Identification of T- and B-cell epitopes of the E7 protein of human papillomavirus type 16. Journal of Virology 65:4681–4690
CrommeF. V.,
MeijerC. J. L. M.,
SnijdersP. J. F.,
UyterlindeA.,
KenemansP.,
HelmerhorstTh.,
SternP. L.,
van den BruleA. J. C.,
WalboomersJ. M. M.1993; Analysis of MHC class I and II expression in relation to presence of HPV genotype in premalignant and malignant cervical lesions. British Journal of Cancer 68:1372–1380
CubieH. A.,
NorvalM.,
CrawfordL.,
BanksL.,
CrookT.1989; Lymphoproliferative response to fusion proteins of human papillomaviruses in patients with cervical intraepithelial neoplasia. Epidemiology and Infection 103:625–632
De Roda HusmanA. M.,
WalboomersJ. M. M.,
MeijerC. J. L. M.,
RisseE. K. J.,
SchipperM. E. I.,
HelmerhorstTh. J. M.,
BlekerO. P.,
van den BruleA. J. C.,
SnijdersP. J. F.1994; Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes using polymerase chain reaction. International Journal of Cancer 56:802–806
Duggan-KeenM.,
KeatingP. J.,
CrommeF. V.,
WalboomersJ. M. M.,
SternP. L.1994; Alterations in major histocompatibility complex expression in cervical cancer: possible consequences for immunotherapy. Papillomaviruses Report 5:3–9
FeltkampM. C. W.,
SmitsH. L.,
VierboomM. P. M.,
MinnaarR. P.,
de JonghB. M.,
DrijfhoutJ. W.,
ter ScheggetJ.,
MeliefC. J. M.,
KastM. W.1993; Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. European Journal of Immunology 23:2242–2249
GlewS. S.,
Duggan-KeenM.,
CabreraT.,
SternP. L.1992; HLAclass II antigen expression in human papillomavirus-associated cervical cancer. Cancer Research 52:4009–4006
GoodmanR. E.,
NestleF.,
YathiM. N.,
GreenJ. M.,
ThompsonC. B.,
NickoloffB. J.,
TurkaL. A.1994; Keratinocyte-derived T cell costimulation induces preferential production of IL-2 and IL-4 but not IFN-y. Journal of Immunology 152:5189–5198
KadishA. S.,
RomneyS. L.,
LedwidgeR.,
TindleR.,
FernandoJ. P.,
ZeeS. Y.,
van RanstM. A.,
BurkR. D.1994; Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific. Journal of General Virology 75:2277–2284
LagaM.,
IcenogleJ. P.,
MarsellaR.,
ManokaA. T.,
NzilaN.,
RyderR. W.,
VermundS. H.,
HeywardW. L.,
NelsonA.,
ReeveW. C.1992; Genital papillomavirus infection and cervical dysplasia-opportunistic complications of HIV infection. International Journal of Cancer 48:682–688
McLeanC. S.,
SterlingJ. S.,
MowatJ.,
NashA. A.,
StanleyM. A.1993; Delayed-type hypersensitivity response to the human papillomavirus type 16 E 7 protein in a mouse model. Journal of General Virology 74:239–245
MullerG.,
SalogaJ.,
GermannT.,
BellinghausenI.,
MohamadzadehM.,
KnopJ.,
EnkH.1994; Identification and induction of human keratinocyte-derived IL-12. Journal of Clinical Investigations 94:1799–1805
RemminkA. J.,
WalboomersJ. M. M.,
HelmerhorstTh. J. M.,
VoorhorstF. J.,
RozendaalL.,
RisseE. K. J.,
MeijerC. J. L. M.,
KenemansP.1995; The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. International Journal of Cancer 61:306–311
SchäferA.,
FriedmannW.,
MielkeM.,
SchwartlanderB.,
KochM. A.1991; The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. American Journal of Obstetrics and Gynecology 164:593–599
ShepherdP. S.,
TranT. T. T.,
RoweA. J.,
CridlandJ. C.,
ComerfordS. A.,
ChapmanM. G.,
RayfieldL. S.1992; T cell responses to the human papillomavirus type 16 E7 protein in mice of different haplotypes. Journal of General Virology 73:1269–1274
SteeleJ. C.,
StankovicT.,
GallimoreP. H.1993; Production and characterization of human proliferative T-cell clones specific for human papillomavirus type-1 E4 protein. Journal of Virology 67:2799–2806
StrangG.,
HicklingJ. K.,
MclndoeG. A. J.,
HowlandK.,
WilkinsonD.,
IkedaH.,
RothbardJ. B.1990; Human T cell responses to human papillomavirus type 16 LI and E6 synthetic peptides: identification of T cell determinants, HLA-DR restriction, and virus type specificity. Journal of General Virology 71:423–431
SuchankovaA.,
KrcmarM.,
KrchnakV.,
HamsikovaE.,
KankaJ.,
VagnerJ.,
VonkaV.1992; Range of HPV-16 E7 antibodies in cervical cancer patients and healthy subjects. International Journal of Cancer 51:837–838
TindleR. W.,
FernandoG. J. P.,
SterlingJ. C.,
FrazerI. H.1991; A ‘public’ T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proceedings of the National Academy of Sciences, USA 88:5887–5891
Van den BruleA. J. C.,
MeijerC. J. L. M.,
BakelsV.,
KenemansP.,
WalboomersJ. M. M.1990; Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction. Journal of Clinical Microbiology 28:2739–2743
ViscidiR. P.,
SunY.,
TsuzakiB.,
BoschF. X.,
MunozN.,
ShahK. V.1993; Serologic response in human papillomavirus-associated invasive cervical cancer. International Journal of Cancer 55:780–784
Zur HausenH.1994; Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. In Human Pathogenic Papillomaviruses pp 131–156 Edited by
Zur HausenH.
Berlin, Heidelberg & New York: Springer-Verlag;
T Cell Proliferative Responses Against Human Papillomavirus Type 16 E7 Oncoprotein are Most Prominent in Cervical Intraepithelial Neoplasia Patients with a Persistent Viral Infection